<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002721</url>
  </required_header>
  <id_info>
    <org_study_id>UNM-2394C</org_study_id>
    <secondary_id>CDR0000064574</secondary_id>
    <secondary_id>NCI-V96-0816</secondary_id>
    <nct_id>NCT00002721</nct_id>
  </id_info>
  <brief_title>Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer</brief_title>
  <official_title>A PHASE I TRIAL OF ESTRAMUSTINE PHOSPHATE AND DOXORUBICIN IN HORMONE REFRACTORY METASTATIC PROSTATE CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in
      treating patients with metastatic recurrent prostate cancer that does not respond to hormone
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Estimate the maximum tolerated dose of weekly intravenous doxorubicin (DOX)
      that can be given in combination with oral estramustine (EM) in patients with metastatic
      prostate cancer refractory to treatment with hormonal agents. II. Assess the frequency of
      expression of the multidrug resistance phenotype in biopsy specimens from these patients.
      III. Assess the response to DOX/EM in these patients.

      OUTLINE: 2-Drug Combination Chemotherapy. Doxorubicin, DOX, NSC-123127; Estramustine, EM,
      NSC-89199.

      PROJECTED ACCRUAL: Three to 18 patients will be entered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1995</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Respond to therapy</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Prostate cancer patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prostate cancer patients that have not responded to hormon therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Prostate cancer patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estramustine phosphate sodium</intervention_name>
    <arm_group_label>Prostate cancer patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>drug resistance inhibition treatment</intervention_name>
    <arm_group_label>Prostate cancer patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Biopsy proven metastatic prostate cancer Biopsy requirement waived
        at principal investigator's discretion if new disease site technically inaccessible and PSA
        elevated Recurrent disease following orchiectomy, estrogen, or gonadotropin-releasing
        hormone agonist therapy If previously irradiated: Progressive disease outside prior
        radiotherapy field required No brain metastases

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Hematopoietic:
        Not specified Hepatic: Bilirubin no greater than 1.5 mg/dL ALT/AST less than 3 times
        greater than normal Renal: Not specified Cardiovascular: Left ventricular ejection fraction
        at least 45% No NYHA class III/IV status No unstable angina Other: No Crohn's disease,
        ulcerative colitis, or other inflammatory bowel syndrome

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        doxorubicin or estramustine Endocrine therapy: See Disease Characteristics At least 30 days
        since flutamide Estrogen or gonadotropin-releasing hormone agonists discontinued prior to
        treatment Radiotherapy: At least 6 weeks since radiotherapy Surgery: Not specified
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Y. Smith, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of New Mexico Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of New Mexico Cancer Research &amp; Treatment Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2004</study_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Estramustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

